The abstract is read at the publisher; the summary is JClub's.
Erythroid-produced intact FGF23 (iFGF23) is a paracrine inhibitor of erythropoiesis in iron-deficient mice, dose-dependently blocking erythroid progenitor differentiation.
- Why it matters: Circulating FGF23 is linked to reduced erythropoiesis in iron deficiency anemia and CKD, but the separate roles of bone- versus erythroid-derived FGF23 in anemia were unclear.
- What they did: Mice with conditional deletion of Fgf23 in osteocytes (Fgf23Dmp1-cKO) or erythroid cells (Fgf23HbB-cKO) were fed control or iron-deficient diets; erythroid Furin deletion increased iFGF23 and worsened anemia, while iFGF23 in culture blocked differentiation and mitochondrial function, suppressed by an FGFR1 inhibitor.
- The result: Erythroid Fgf23 deletion corrected ID-induced anemia and prevented CKD anemia, implying erythroid-expressed FGF23 contributes to anemia through direct paracrine FGFR1 activation in erythroid precursors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.